Dr. Kumar’s Take
For patients who have already had C. difficile disease (CDD), recurrence is a serious risk and often harder to manage than the initial episode. This trial tested S. boulardii alongside standard antibiotics and found a real reduction in recurrence, but only in the patients who came in with a prior episode. In first-episode disease, the yeast added nothing I can point to. That split is the clinically useful part: I would reserve this adjunct for the recurrent group.
Key Takeaways
- Adults with active C. difficile disease were randomized to standard antibiotic therapy plus S. boulardii (1 g/day) or placebo for 4 weeks.
- They were followed for another 4 weeks after therapy to monitor recurrence.
- On multivariate analysis, S. boulardii plus standard antibiotics carried a significantly lower relative risk of recurrence than placebo plus standard antibiotics: RR 0.43 (95% CI, 0.20 to 0.97).
- In the subset with previous CDD episodes, recurrence was 34.6% with S. boulardii versus 64.7% with placebo (p = .04).
- In patients with an initial episode, recurrence was 19.3% versus 24.2% with placebo (p = .86), no demonstrated benefit.
- A history of prior CDD episodes markedly increased the likelihood of further recurrences.
- There were no serious adverse reactions associated with S. boulardii.
Actionable Tip
In patients with recurrent C. difficile disease, when prescribing vancomycin or metronidazole, consider adding S. boulardii at 1 g daily for a 4-week course, then continue watching for recurrence for another 4 weeks after therapy ends.
Study Summary
McFarland and colleagues ran a double-blind, randomized, placebo-controlled, parallel-group trial in adult patients with active C. difficile disease. Patients received standard antibiotic therapy plus either S. boulardii or placebo for 4 weeks and were followed for an additional 4 weeks. The outcome of interest was recurrence of active CDD, analyzed with multivariate methods to control for other recurrence risk factors.
Study Design
- Population: 124 eligible consenting adults with active CDD, 64 enrolled with an initial episode and 60 with a history of at least one prior episode. Patients immunosuppressed due to acquired immunodeficiency syndrome or cancer chemotherapy within 3 months were not eligible.
- Setting: National referral study of ambulatory or hospitalized patients drawn from three main study coordinating centers.
- Interventions:
- Standard antibiotic (vancomycin hydrochloride or metronidazole) plus oral S. boulardii 1 g/day for 4 weeks
- Standard antibiotic plus placebo for 4 weeks
- Follow-up: An additional 4 weeks after therapy to assess recurrence
- Primary outcome: Recurrence of active C. difficile disease
Results
- Overall effect on recurrence: Relative risk 0.43 (95% CI, 0.20 to 0.97) for S. boulardii plus standard antibiotics compared with placebo plus standard antibiotics, on multivariate analysis.
- Recurrence in patients with prior C. difficile episodes:
- 34.6% in the S. boulardii group
- 64.7% in the placebo group (p = .04)
- Recurrence in patients with an initial episode:
- 19.3% in the S. boulardii group
- 24.2% in the placebo group (p = .86)
- Risk factor: A history of CDD episodes dramatically increased the likelihood of further recurrences.
- Safety: No serious adverse reactions associated with S. boulardii.
Biological Rationale
- C. difficile recurrence follows disruption of the normal gut flora by antibiotics, which leaves the organism free to persist and re-emerge once therapy stops.
- S. boulardii is a yeast, so it is not suppressed by the antibacterial agents used to treat CDD and can be given alongside them.
- Adding it to vancomycin or metronidazole is intended to support the gut environment during the window when recurrence risk is highest.
Strengths & Limits
Strengths:
- Double-blind, randomized, placebo-controlled parallel-group design, which supports causal inference.
- Enrolled a substantial number of patients with prior episodes, the group at greatest risk.
- Multivariate analysis controlled for other risk factors for recurrence.
- Follow-up continued for 4 weeks beyond the end of therapy.
Limitations:
- Published in 1994, so diagnostic and microbiologic standards differ from current practice.
- No benefit was demonstrated in the initial-episode group, and with 64 such patients the trial may not have been able to detect a smaller effect.
- Only vancomycin and metronidazole were used as the companion antibiotics, so the findings may not extend to newer regimens.
- Immunosuppressed patients, including those with AIDS or recent cancer chemotherapy, were excluded, so the safety record does not extend to them.
Related Studies and Research
- Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea: meta‑analysis
- Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: RCT
- SB + Amoxicillin‑Clavulanate Effects on Gut Microbiota (RCT)
- High‑Dose Vancomycin + SB for Recurrent C. difficile
- 🎙️ Saccharomyces boulardii Explained: Podcast Episode
FAQ
Why was there no benefit for a first episode of C. difficile?
Recurrence was 19.3% with S. boulardii versus 24.2% with placebo in that group, a difference that did not reach statistical significance (p = .86). With 64 patients enrolled at a first episode, a modest effect could have escaped detection, and baseline recurrence risk was lower in that group to begin with.
Was 1 g/day tolerated?
Patients took 1 g/day for 4 weeks and there were no serious adverse reactions associated with S. boulardii. Patients immunosuppressed by AIDS or by cancer chemotherapy within 3 months were excluded from the trial, so I would not read the safety result as covering them.
Which patients does this apply to?
The demonstrated benefit is in patients with recurrent CDD, meaning at least one prior episode. That was the group in which recurrence fell from 64.7% to 34.6%.
Bottom Line
For patients with recurrent C. difficile disease, adding S. boulardii at 1 g/day to standard antibiotic therapy lowered recurrence over the 4 weeks of treatment and the 4 weeks that followed, from 64.7% to 34.6%. For a first episode, the trial showed no benefit. That is how I would use it: as an adjunct in recurrent disease, not routinely.
